Best Stocks Under $2.00 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. #1 - JD Sports FashionOTCMKTS:JDSPYStock Price: $1.95 (-$0.11)Average Trading Volume: 3,386 sharesConsensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $206.67 (10,498.3% Upside)JD Sports Fashion plc engages in the retail of branded sports fashion and outdoor clothing, footwear, accessories, and equipment for kids, women, and men. It operates through Sports Fashion and Outdoor segments. The company also retails leisure goods, sports goods, fishing gear, camping goods, boats, and bicycles, as well as distributes sports apparel and accessories, footwear, and apparel. It offers its products under the JD, Size?, Footpatrol, Finish Line, Shoe Palace, DTLR, Livestock, Sprinter, Sport Zone, Sizeer, JD Gyms, Tessuti, Scotts, Go Outdoors, Blacks, Millets, Tiso, Ultimate Outdoors, Fishing Republic, and Naylors brands. The company also operates online business. In addition, it licenses fashion brands and operates fitness centers; operates as online own label women's fashion retailer; and manufactures and distributes professional fitness equipment. The company has operations in the United Kingdom, Andorra, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Latvia, Lithuania, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Republic of Ireland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain and the Canary Islands, Sweden, Thailand, and the United Arab Emirates. The company was founded in 1981 and is headquartered in Bury, the United Kingdom. JD Sports Fashion plc is a subsidiary of Pentland Group Limited. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - CES Energy SolutionsOTCMKTS:CESDFStock Price: $1.85 (-$0.02)PE Ratio: 6.40Average Trading Volume: 11,671 sharesP/E Ratio: 6.4Dividend Yield: 6.45%Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.28 (131.2% Upside)CES Energy Solutions Corp., together with its subsidiaries, designs, implements, and manufactures advanced consumable fluids and specialty chemicals. It provides solutions for drill-bit, point of completion and stimulation, wellhead and pump-jack, and pipeline and midstream markets. The company's solutions include corrosion inhibitors, demulsifiers, H2S scavengers, paraffin control products, surfactants, scale inhibitors, biocides, and other specialty products. It also designs and implements drilling fluid systems and completion solutions for oil and gas producers; designs and manufactures production and specialty chemicals for use in the oil and natural gas production markets, the stimulation and fracturing markets, and the pipeline and midstream markets; and operates trucks and trailers to transport products in the oil and gas industry. In addition, the company provides environmental consulting, water management services, and drilling fluids waste disposal services primarily to oil and gas producers; and laboratory services. It serves oil and natural gas industry, including multinational producers, intermediate oil and natural gas operators, independent juniors, and joint ventures, as well as pipeline and mid-stream markets in western Canada and the United States. The company was formerly known as Canadian Energy Services & Technology Corp. and changed its name to CES Energy Solutions Corp. in June 2017. CES Energy Solutions Corp. was incorporated in 1986 and is headquartered in Calgary, Canada.#3 - Taseko MinesNYSEAMERICAN:TGBStock Price: $1.39 (-$0.03)PE Ratio: -17.31Market Cap: $409.55 millionAverage Trading Volume: 869,517 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.73 (97.1% Upside)Taseko Mines Ltd. operates as a mining company engaged in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.#4 - Integra ResourcesNYSEMKT:ITRGStock Price: $1.00 (+$0.01)PE Ratio: -1.43Market Cap: $68.09 millionAverage Trading Volume: 51,534 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.63 (362.5% Upside)Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.#5 - SaipemOTCMKTS:SAPMYStock Price: $0.27PE Ratio: 0.83Average Trading Volume: 44,547 sharesP/E Ratio: 0.8Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.95 (633.1% Upside)Saipem SpA provides energy and infrastructure solutions worldwide. The company operates through divisions Offshore Engineering & Construction (E&C), Onshore Engineering & Construction, and Offshore Drilling. It offers development of subsea fields and pipelaying; installation and lifting of offshore structures; and engineering, implementation, installation, maintenance, modification, and decommissioning activities. The company also provides biorefineries, geothermal energy, carbon capture, wind and solar energy, waste to energy, and renewables and green technologies; high-speed rail; premium, engineering, and smart maintenance services; and offshore and onshore services. In addition, the company provides procurement, project management, construction, and engineering integrated services for the energy industry and public markets. Saipem S.p.A. was founded in 1957 and is headquartered in Milan, Italy.#6 - Argonaut GoldOTCMKTS:ARNGFStock Price: $0.44 (-$0.02)PE Ratio: -5.72Average Trading Volume: 429,435 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.00 (129.6% Upside)Argonaut Gold, Inc. engages in the exploration, mine development, and production activities on gold-bearing properties. Its primary assets are the production stage El Castillo mine and San Agustin mine, which together form the El Castillo Complex in Durango, Mexico and the production stage La Colorada mine in Sonora, Mexico. The company was founded on April 3, 2007 and is headquartered in Reno, NV.#7 - Enthusiast GamingNASDAQ:EGLXStock Price: $0.41 (-$0.01)PE Ratio: -1.08Market Cap: $64.79 millionAverage Trading Volume: 140,811 sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.20 (918.9% Upside)Enthusiast Gaming Holdings Inc., an integrated gaming entertainment company, engages in the media, content, entertainment, and esports businesses in Canada, the United States, England and Wales, and internationally. The company owns and operates video-gaming expo; owns and manages esports teams for various games comprising Apex Legends, Rocket League, World of Warcraft, Call of Duty: Mobile, Rainbow Six Siege, PlayerUnknown's Battlegrounds, Call of Duty: Warzone, Super Smash Bros: Melee, and Super Smash Bros: Ultimate; and produces and programs approximately 20 weekly shows across advertising-based video on demand (AVOD) and over-the-top (OTT) channels, as well as represents approximately 500 gaming influencers on YouTube and Twitch. It also owns and operates approximately 50 websites that contain news, reviews, videos, live streams, blog posts, tips, chats, message boards, other video-gaming related content, and casual games. In addition, the company operates Luminosity Gaming, an eSports organization; operates approximately 25 video game networking events; and hosts B2B and consumer mobile gaming events. Enthusiast Gaming Holdings Inc. is headquartered in Toronto, Canada.#8 - Fortress BiotechNASDAQ:FBIOStock Price: $0.59 (+$0.01)PE Ratio: -0.59Market Cap: $77.91 millionAverage Trading Volume: 926,937 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.50 (839.5% Upside)Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.#9 - Leap TherapeuticsNASDAQ:LPTXStock Price: $0.62 (-$0.06)PE Ratio: -0.87Market Cap: $80.59 millionAverage Trading Volume: 1.74 million sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.80 (355.3% Upside)Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.#10 - Passage BioNASDAQ:PASGStock Price: $0.96 (-$0.02)PE Ratio: -0.41Market Cap: $53.64 millionAverage Trading Volume: 111,135 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.80 (815.7% Upside)Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.#11 - iCADNASDAQ:ICADStock Price: $1.20 (-$0.08)PE Ratio: -2.22Market Cap: $32.57 millionAverage Trading Volume: 168,321 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.90 (225.0% Upside)iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.#12 - AtrecaNASDAQ:BCELStock Price: $1.21 (+$0.03)PE Ratio: -0.50Market Cap: $47.38 millionAverage Trading Volume: 145,620 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.75 (788.4% Upside)Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.#13 - Clearside BiomedicalNASDAQ:CLSDStock Price: $1.28PE Ratio: -2.25Market Cap: $78.93 millionAverage Trading Volume: 96,476 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.00 (368.8% Upside)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.#14 - Chicken Soup for the Soul EntertainmentNASDAQ:CSSEStock Price: $1.34 (-$0.11)PE Ratio: -0.17Market Cap: $42.39 millionAverage Trading Volume: 394,588 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.00 (422.4% Upside)Chicken Soup for the Soul Entertainment, Inc. is an emerging growth company, which engages in the production and distribution of video content. The firm distributes and exhibits video on-demand content directly to consumers across all digital platforms, such as smartphones, tablets, gaming consoles. It also provides distribution of movies and television series worldwide to consumers through license agreements across all media, including theatrical, home video, pay-per-view, free, cable and pay television, VOD and new digital media platforms worldwide. The company was founded on May 4, 2016 and is headquartered in Cos Cob, CT.#15 - AraviveNASDAQ:ARAVStock Price: $1.65 (-$0.06)PE Ratio: -0.74Market Cap: $102.33 millionAverage Trading Volume: 287,168 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.20 (457.6% Upside)Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.#16 - Outlook TherapeuticsNASDAQ:OTLKStock Price: $1.73 (-$0.01)Market Cap: $446.60 millionAverage Trading Volume: 1.39 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.60 (223.7% Upside)Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.#17 - Atai Life SciencesNASDAQ:ATAIStock Price: $1.75 (-$0.04)PE Ratio: -1.84Market Cap: $290.52 millionAverage Trading Volume: 1.24 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.80 (631.4% Upside)Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.#18 - 23andMeNASDAQ:MEStock Price: $1.93 (-$0.08)PE Ratio: -2.80Market Cap: $927.12 millionAverage Trading Volume: 3.03 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.50 (185.0% Upside)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications; and Lemonaid telehealth platform, patients can access affiliated licensed healthcare professionals for medical consultation and treatment for several common conditions, as well as research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline plc to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.#19 - AgenusNASDAQ:AGENStock Price: $1.99 (-$0.05)PE Ratio: -2.43Market Cap: $694.27 millionAverage Trading Volume: 4.93 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.33 (268.1% Upside)Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.#20 - AcuityAdsNYSE:ATYStock Price: $1.74 (+$0.11)PE Ratio: -173.83Market Cap: $98.88 millionAverage Trading Volume: 56,165 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.43 (97.0% Upside)AcuityAds Holdings, Inc. engages in the provision of digital advertising solutions. It operates through the following geographical segments: Unites States, Canada, and Europe and Other. The company was founded by Tal Hayek, Nathan Mekuz, Rachel Kapcan, and Joe Ontman on October 9, 2009 and is headquartered in Toronto, Canada.#21 - CleneNASDAQ:CLNNStock Price: $1.03 (-$0.03)PE Ratio: -2.64Market Cap: $80.75 millionAverage Trading Volume: 76,890 sharesConsensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.33 (903.2% Upside)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.#22 - AffimedNASDAQ:AFMDStock Price: $0.71 (+$0.01)PE Ratio: -1.01Market Cap: $106.02 millionAverage Trading Volume: 1.02 million sharesConsensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.50 (674.8% Upside)Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.#23 - Greenbrook TMSNASDAQ:GBNHStock Price: $0.72 (-$0.03)PE Ratio: -0.29Market Cap: $13.35 millionAverage Trading Volume: 34,242 sharesConsensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.06 (603.1% Upside)Greenbrook Tms, Inc. engages in the control and operation of a network of outpatient mental health services centers that specialize in the provision of Transcranial Magnetic Stimulation (TMS) therapy and other treatment modalities for the treatment of depression and related psychiatric services. The company was founded on February 9, 2018 and is headquartered in Toronto, Canada.#24 - Adaptimmune TherapeuticsNASDAQ:ADAPStock Price: $0.99 (-$0.02)PE Ratio: -1.43Market Cap: $152.71 millionAverage Trading Volume: 703,519 sharesConsensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.12 (519.8% Upside)Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.#25 - AgileThoughtNASDAQ:AGILStock Price: $0.80 (+$0.01)PE Ratio: -0.72Market Cap: $39.49 millionAverage Trading Volume: 63,702 sharesConsensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.80 (625.7% Upside)AgileThought, Inc. provides digital transformation services in the United States and Latin America. It offers organizational transformations, training and certifications, and product management services. The company provides application engineering and DEVOPS, cloud architecture and migration, data analytics, automation, application modernization, UX/UI design, artificial intelligence, and machine learning services. In addition, it offers lifecycle management support and multi cloud services. The company serves professional services, healthcare, pharmacy, financial services, energy, and utilities industries. AgileThought, Inc. was founded in 2000 and is headquartered in Irving, Texas. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks Electric Vehicle Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Cheap Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $3.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition Will NIO Partake In China's Economic Awakening?Can The Digital Economy Revive DocuSign Stock?Newly Public Fluence Energy Near Buy Zone With Strong MomentumBeyond the Vision Pro: 3 Augmented Reality Small Caps to WatchBJ's Restaurants' Approaching Buy Point As Earnings Surge 150%Tax Software Specialist Vertex In Buy Zone After Base BreakoutWill Plug Power’s Deal With Energy Vault Move The Needle? Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.